Drug search by name

Mektovi and Cardiomyopathy

Result of checking the interaction of drug Mektovi and disease Cardiomyopathy for safety when used together.

Check result:

Mektovi <> Cardiomyopathy

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Cardiomyopathy, manifesting as left ventricular dysfunction associated with symptomatic or asymptomatic decreases in ejection fraction, has been reported in patients treated with binimetinib in combination with encorafenib. The median time to first occurrence of left ventricular dysfunction (any grade) in patients receiving treatment was 3.6 months (range 0 to 21 months). Cardiomyopathy resolved in 87% of the patients. Ejection fraction should be assessed by echocardiogram or MUGA scan prior to initiating treatment, one month after initiating treatment, and then every 2 to 3 months during treatment. The safety of this therapy has not been established in patients with a baseline ejection fraction that is either below 50% or below the institutional lower limit of normal (LLN). Patients with cardiovascular risk factors should be monitored closely when treated with binimetinib.

Mektovi

Generic Name: binimetinib

Brand Name: Mektovi

Synonyms: n.a.

What is Mektovi?